Suppr超能文献

完善结直肠癌中DNA倍体状态的预后意义:一项前瞻性流式细胞术研究。

Refining the prognostic significance of DNA ploidy status in colorectal cancer: a prospective flow cytometric study.

作者信息

Jones D J, Moore M, Schofield P F

机构信息

Department of Surgery, University Hospital of South Manchester, UK.

出版信息

Int J Cancer. 1988 Feb 15;41(2):206-10. doi: 10.1002/ijc.2910410208.

Abstract

A consecutive series of 123 colorectal cancers, prospectively followed for 3 years, was studied to determine if the prognostic significance of DNA ploidy related to: (a) thresholds used to define DNA aneuploidy, or (b) aneuploid sub-groups defined by DNA index (DI) and peak size. Aneuploidy was defined using 3 methods depending on the minimum proportion of nuclei considered to constitute an aneuploid peak; type 1, 5%; type 2, 10%; type 3, 10% if DI is 1.1-1.8, but 15% if DI is 1.9-2.1. DNA aneuploidy rates were type 1, 75%; type 2, 67%; type 3, 58%. The significance of clinical and pathological correlations varied with the use of different methods. All were associated with a significant DNA diploid survival advantage which was strongest for type 3 (p = 0.006). DI was unrelated to survival irrespective of the presence or absence of an associated S/G2; 33% with a DI of 1.1-1.8 and 35% with a DI of 1.9-2.1 survived. Prognosis was inversely proportional to aneuploid peak size, 48% with small peaks (less than 20%), 30% with intermediate peaks (greater than 20% less than 40%), but none with large peaks (greater than 40%) survived (p = 0.03). We conclude that: (a) thresholds used to define DNA aneuploidy affect the prognostic significance of DNA ploidy; (b) survival is independent of the DI of aneuploid peaks; and (c) measurement of aneuploid peak size refines the prognostic value of DNA ploidy.

摘要

对连续的123例结肠直肠癌进行了为期3年的前瞻性随访研究,以确定DNA倍性的预后意义是否与以下因素相关:(a) 用于定义DNA非整倍体的阈值,或(b) 由DNA指数(DI)和峰大小定义的非整倍体亚组。根据被认为构成非整倍体峰的细胞核的最小比例,使用3种方法定义非整倍体;1型,5%;2型,10%;3型,如果DI为1.1 - 1.8,则为10%,但如果DI为1.9 - 2.1,则为15%。DNA非整倍体率分别为:1型,75%;2型,67%;3型,58%。临床和病理相关性的意义因使用不同方法而有所不同。所有这些都与显著的DNA二倍体生存优势相关,其中3型最强(p = 0.006)。无论是否存在相关的S/G2,DI均与生存无关;DI为1.1 - 1.8的患者中有33%存活,DI为1.9 - 2.1的患者中有35%存活。预后与非整倍体峰大小成反比,小峰(小于20%)的患者中有48%存活,中等峰(大于20%小于40%)的患者中有30%存活,但大峰(大于40%)的患者无一存活(p = 0.03)。我们得出结论:(a) 用于定义DNA非整倍体的阈值会影响DNA倍性的预后意义;(b) 生存与非整倍体峰的DI无关;(c) 非整倍体峰大小的测量可提高DNA倍性的预后价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验